Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Pharmacy Benefit Managers (PBMs)
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 1216 Results
Context Matters on Health Statistics
A single number doesn’t always tell the full story, and that’s the case when it comes to a recent report from AHIP asking how our health care premium dollars are being spent.
Survey Data Shows Physicians See Pharmaceuticals as Leading Contributor to Improved Health Outcomes
Research by RTI Health Solutions and the National Pharmaceutical Council shows the value of biopharmaceutical and pharmaceutical innovations to improving patient health.
FDA Clarifies What Information Can Be Exchanged With Health Decision-Makers
With the release of two guidance documents this week, the US Food and Drug Administration took significant steps to modernize how health care information is communicated. The final guidance released…
Financial Impact of HSA-HDHP Reform to Improve Access to Chronic Disease Management Medications
According to an issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication adherence…
High Spending Growth Rates For Key Diseases Were Driven By Technology And Demographic Factors
Research published in the June 2018 edition of Health Affairs shows that increases in health care spending on key diseases can be attributed to several factors: the use of new and often…
Evaluation of Person-level Heterogeneity of Treatment Effects in Published Multiperson N-of-1 Studies: Systematic Review and Reanalysis
To understand when and how individual treatment effects are examined, conducted and reported, this study evaluated existing multiperson N-of-1 studies, which can identify whether an intervention is…
NPC at ISPOR 2018: Gathering and Curating Real-World Data
The use and importance of real-world evidence (RWE) in clinical decision-making has been frequently cited by Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb, so it’s not surprising…
NPC in in Specialty Pharmacy Times: Aiming for Value Over Volume in Cancer Drug Spending
In his latest column for Specialty Pharmacy Times, NPC President Dan Leonard takes a closer look at a presidential panel's report on "Promoting Value, Affordability, and Innovation in Cancer Drug…
Could expanding pre-deductible coverage help those with chronic conditions?
According to a new issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication…
One Size Doesn’t Fit All: The Limitations Of Assuming Data Consistency In Health Spending
The Health Affairs Blog today published a piece from RTI International, RTI Health Solutions and National Pharmaceutical Council researchers detailing the assumptions made – and the…
What’s Next in Precision Medicine?
Personalized medicine is greatly changing health care practices, as well as how innovative treatments are being developed.
NPC in Chain Drug Review: The Impact of PBM Rebates at the Pharmacy Counter
There is a mismatch between the savings pharmacy benefit managers (PBMs) boast about and the pinch patients are feeling in their pockets, as well as the disconnect between the role employers…
Regulatory Barriers Impair Alignment of Biopharmaceutical Price and Value
This white paper highlights the challenges biopharmaceutical manufacturers and payers face when developing value-based contracts.
Breaking Down Regulatory Barriers to Value Pricing for Prescription Drugs
Paying for prescription medicines based on their value to patients is increasingly seen as a promising technique to combat rising medication costs. But while other parts of the health care sector are…